我国创新药加速跑！政策合力打通进院“最后一公里”

Group 1 - The core viewpoint of the article highlights the introduction of supportive policies for the development of innovative drugs in China, aimed at enhancing accessibility and expediting the process from market entry to patient access [1][3]. Group 2 - The Shanghai Municipal Health Commission mandates that the entire hospital admission process for innovative drugs be completed within 15 working days, and costs for national negotiated drugs during clinical use will not be included in the annual medical insurance quota [5]. - Beijing has expanded payment channels for innovative medicines, establishing a dynamic adjustment mechanism for the "Beijing Universal Health Insurance" special drug list, which has been upgraded to 121 types for the 2025 fiscal year [7]. - In 2023, Beijing has facilitated the rapid listing of 51 innovative drugs on its drug procurement platform through a green channel, with over 100 tertiary medical institutions participating in the national negotiated drug "dual channel" pilot [9]. Group 3 - The National Medical Insurance Administration has made seven rounds of adjustments to the drug list, incorporating a total of 149 innovative drugs into the medical insurance directory, with 33 of the 91 new drugs added in 2024 achieving "approval and inclusion in the same year" [11]. - The time taken for new drugs to be included in the medical insurance directory has decreased from approximately five years to around one year, with about 80% of innovative drugs being included in the insurance payment range within two years of market entry [11].